Mucosal and Microbiota Changes During Acute Campylobacteriosis
ConditionIrritable Bowel Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorMayo Clinic
About this trial
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
No abdominal surgery (except appendectomy and cholecystectomy)
Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter
Disqualifiers
History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease.
History of gastroenteritis in six months prior to Campylobacter enteritis
Pregnancy
Trial population
Patients with acute Campylobacter infection
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
150 Participants
are grouped into 1 trial groupGroup A: Acute Campylobacter
Trial outcomes
Primary outcomes
1
Development of IBS is the endpoint.
Number of Subjects Who Develop Irritable Bowel Syndrome After Campylobacter Infection
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov